Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met
Efthimios Dardiotis1, Pantelitsa Koutsou, Eleni Zamba-Papanicolaou
1The Cyprus Institute of Neurology and Genetics, P.O. Box 23462, 1683 Nicosia, Cyprus.
Journal of the Neurological Sciences
|June 5, 2009
Summary
This study identified specific gene polymorphisms that may influence the age of onset for Familial Amyloidotic Polyneuropathy (FAP) TTR Val30Met. These findings could lead to new therapeutic strategies for this genetic disorder.
Area of Science:
- Genetics
- Neurology
- Molecular Biology
Background:
- Familial Amyloidotic Polyneuropathy (FAP) TTR Val30Met is a lethal inherited neuropathy caused by a transthyretin (TTR) gene mutation.
- Amyloid deposits from mutated TTR affect the nervous system, heart, and kidneys, with significant variability in disease onset and penetrance.
- Environmental and genetic factors are suspected to influence FAP variability, but no specific modifier genes have been identified.
Purpose of the Study:
- To investigate potential genetic modifiers influencing the age of onset and penetrance of FAP TTR Val30Met.
- To identify correlations between polymorphisms in chaperone protein genes and the clinical presentation of FAP.
- To explore the role of complement C1Q and serum amyloid P genes in FAP pathogenesis.
Main Methods:
- Candidate modifier genes encoding chaperone proteins co-localized with TTR deposits were selected.
- Genetic sequencing of TTR, APCS, and C1Q genes was performed on 71 TTR Val30Met carriers and 59 controls.
- APOE genotyping and analysis of single nucleotide polymorphisms (SNPs) were conducted to assess correlations with disease onset.
Main Results:
- Four novel and four known single nucleotide substitutions were identified in the studied genes.
- A significant correlation was found between a specific polymorphic site in C1QA (rs172378), a site in C1QC (rs9434), and the TTR Val30Met epsilon2 allele with the age of disease onset (p<0.05).
Conclusions:
- Specific polymorphisms in complement C1Q genes (C1QA and C1QC) and the APOE epsilon2 allele are associated with the age of onset in FAP TTR Val30Met.
- Identification of these modifier genes provides insights into the variable phenotype of FAP.
- Further research into modifier genes and their protein products may pave the way for novel therapeutic interventions for FAP.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...